Talimogene Laherparepvec: A groundbreaking viral therapy for late stage melanoma: Difference between revisions

From MicrobeWiki, the student-edited microbiology resource
No edit summary
Line 2: Line 2:
==Introduction==
==Introduction==


[[Image: http://darwin.bio.uci.edu/~faculty/wagner/hsvimg02.jpg|thumb|300px|right|<b> Figure 1:</b>  <i> </i>  <i>  </i>   
[[ http://darwin.bio.uci.edu/~faculty/wagner/hsvimg02.jpg|thumb|300px|right|<b> Figure 1:</b>  <i> </i>  <i>  </i>   


[[http://darwin.bio.uci.edu/~faculty/wagner/hsvimg01z.jpg|thumb|300px|right|


<br>By Alex Fazioli<br>
<br>By Alex Fazioli<br>
Line 21: Line 20:
<br><b>Subscript:</b> H<sub>2</sub>O
<br><b>Subscript:</b> H<sub>2</sub>O
<br><b>Superscript:</b> Fe<sup>3+</sup>
<br><b>Superscript:</b> Fe<sup>3+</sup>
<br>Introduce the topic of your paper.  What is your research question? What experiments have addressed your question?  Applications for medicine and/or environment?<br>
Sample citations: <ref>[http://www.plosbiology.org/article/fetchObject.action?uri=info%3Adoi%2F10.1371%2Fjournal.pbio.1000005&representation=PDF Hodgkin, J. and Partridge, F.A. "<i>Caenorhabditis elegans</i> meets microsporidia: the nematode killers from Paris." 2008. PLoS Biology 6:2634-2637.]</ref>
<ref>[http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3847443/ Bartlett et al.: Oncolytic viruses as therapeutic cancer vaccines. Molecular Cancer 2013 12:103.]</ref>
<br><br>A citation code consists of a hyperlinked reference within "ref" begin and end codes.


==Classification==
==Classification==

Revision as of 20:44, 2 April 2018

This is a curated page. Report corrections to Microbewiki.

Introduction

[[ http://darwin.bio.uci.edu/~faculty/wagner/hsvimg02.jpg%7Cthumb%7C300px%7Cright%7C Figure 1:



By Alex Fazioli

Talimogene Laherparepvec (T-VEC) is an engineered Herpes simplex virus type 1 designed to specifically target, reproduce, and lyse human tumor cells [1]. T-VEC also produces granulocyte macrophage colony-stimulating factor (GM-CSF) to improve the antitumor immune response within the human body upon the lysis of tumor cells [1]. T-VEC avoids infecting non-cancerous cells by having all copies of two key neurovirulence factor genes deleted RL1 and US12 [2]. The deletion of the US12 gene puts its promoter in close proximity to the US11 increasing its expression which has been shown to increase the ability of T-VEC to replicate within tumour cells [3].


Double brackets: [[
Filename: PHIL_1181_lores.jpg
Thumbnail status: |thumb|
Pixel size: |300px|
Placement on page: |right|
Legend/credit: Electron micrograph of the Ebola Zaire virus. This was the first photo ever taken of the virus, on 10/13/1976. By Dr. F.A. Murphy, now at U.C. Davis, then at the CDC.
Closed double brackets: ]]

Other examples:
Bold
Italic
Subscript: H2O
Superscript: Fe3+

Classification

Baltimore classification: dsDNA
Family: Herpesviridae
Virion: Enveloped
Capsid symmetry: Icosahedral
Replication site: Nucleus and cytoplasm

Section 2

Include some current research, with at least one figure showing data.

Section 3

Include some current research, with at least one figure showing data.

Section 4

Conclusion

References


1. Andtbacka, R. H., Kaufman, H. L., Collichio, F., Amatruda, T., Senzer, N., Chesney, J., ... & Milhem, M. (2015). Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. Journal of clinical oncology, 33(25), 2780-2788.

2. Pol, J., Kroemer, G., & Galluzzi, L. (2016). First oncolytic virus approved for melanoma immunotherapy.

3. Liu, B. L., Robinson, M., Han, Z., Branston, R. H., English, C., Reay, P., & ... Coffin, R. S. (2003). ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene Therapy, 10(4), 292.




Authored for BIOL 238 Microbiology, taught by Joan Slonczewski, 2018, Kenyon College.

Retrieved from "https://microbewiki.kenyon.edu/index.php?title=Talimogene_Laherparepvec:_A_groundbreaking_viral_therapy_for_late_stage_melanoma&oldid=132867"